Advances in colorectal cancer research from 2017 annual meeting of the American Society of Clinical Oncology
10.3760/cma.j.issn.1673-9752.2017.07.006
- VernacularTitle:2017年美国临床肿瘤学会年会结直肠癌研究进展解析
- Author:
Gong CHEN
- Keywords:
Colorectal neoplasms;
Therapy;
Progress;
American Society of Clinical Oncology
- From:
Chinese Journal of Digestive Surgery
2017;16(7):668-673
- CountryChina
- Language:Chinese
-
Abstract:
It is plentiful about the 289 abstracts for the colorectal cancer (CRC) in the 2017 annual meeting of the American Society of Clinical Oncology (ASCO),which include:(1) comparison between long and short courses of postoperative adjuvant chemotherapy for stage Ⅲ CRC in the early diseases,applications of the full course of neoadjuvant therapy for locally advanced rectal cancer and laparoscopic total mesorectal excision for rectal cancer.(2) The use of Vitamin D3 and selective interstitial radiotherapy for metastatic CRC in the advanced diseases showed an encouraging efficacy.Patients with BRAF mutation and poor prognosis underwent a combination therapy of BRAF inhibitor and epidermal growth factor receptor (EGFR),which has created a new situation for precision therapy.And China's domestically designed Fruquintinib (small-molecule kinase inhibitor) and EGFR CMABO09 have showed better clinical efficacies in the second-line therapy.(3) On the precision medicine and translational researches,clinical value of consensus of molecular subtypes is being revealed and liquid biopsy is advantageous to predict postoperative tumor recurrence.These new therapies and researches would impact the clinical practices,promote clinical development and benefit the patients.
